Synthesis and controlled release evaluation of (E)-1-(2,2-dichloro-1-phenylvinyl)-2-phenyldiazene loaded chitosan nanoparticles

Nanoparticles, due to their specific properties, have been used in a variety of applications in recent years, such as peptide and protein transport, drug targeting and controlled release in medicine and nanotechnology. One of the natural polymers widely used in the synthesis of nanoparticles is chitosan. Chitosan is often preferred in nanoparticle carrier systems because of its biocompatibility, biodegradability and unique cationic character. (e) -1- (2,2-dichloro-1-phenylvinyl) -2-phenyldiazane which synthesized by carrying out the catalytic olefination reaction is a novel organic compound with a high physiological activity. Antimicrobial activity of the molecule has been investigated by using microorganisms such as St. aureus, Ps. aeruginoza, E.coli ve Cand. albicans. In addition, antimicrobial activity has been compared with ethyl alcohol and widely used drugs such as, furacilin and nitofungin and it has been proved that has strong antibacterial and antifungal properties. In this study, it is aimed to increase the biocompatibility and bioavailability of the molecule by loading (e)-1-(2,2-dichloro-1-phenylvinyl)-2-phenyldiazene into biocompatible and biodegradable chitosan nanoparticles and investigate controlled release of the molecule from synthesized nanoparticle system. The zeta potential and particle size of the synthesized nanoparticles were measured using a Zeta Sizer, characterization of nanoparticles were performed by FT-IR, UV-Vis and SEM analysis. Encapsulation efficiency, loading capacity and reaction yield of nanoparticles were calculated and release of (e)-1-(2,2-dichloro-1-phenylvinyl)-2-phenyldiazene loaded nanoparticles were performed in PBS buffer by using cumulative release technique. In consequence of the study, optimum nanoparticles with the expected properties were obtained and it was determined that the rates of drug release varied between 38% - 58% at the end of the 30th day. It is anticipated that using polymeric nanoparticles as a drug carrier will decrease the frequency of drug dose by controlling the level of active agent in blood, thus will increase patient compliance. Furthermore, it is considered that the synthesized nanoparticles would be a model in long term and controlled release for similar antimicrobial molecules. Keywords: nanoparticle, chitosan, (e)-1-(2,2-dichloro-1-phenylvinyl)-2-phenyldiazene, drug release